DDInter1729 DDInter1409
Sulindac is a nonsteroidal anti-inflammatory drug (NSAID) of the arylalkanoic acid class that is marketed by Merck under the brand name Clinoril. Like other NSAIDs, it may be used in the treatment of acute or chronic inflammatory conditions. Sulindac is a prodrug, derived from sulfinylindene, that is converted _in vivo_ to an active sulfide compound by liver enzymes. There is evidence from some studies that sulindac may be associated with fewer gastrointestinal side effects than other NSAIDs, except for the cyclooxygenase-2 (COX-2) inhibitor drug class. This may be due to the sulfide metabolite undergoing enterohepatic circulation thus maintaining constant blood levels of the compound without inducing gastrointestinal effects, where the drug is excreted in the bile and then reabsorbed from the intestines. While its full mechanism of action is not fully understood, sulindac
Multiple Sclerosis (MS) is a chronic and inflammatory autoimmune disease of the central nervous system, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792] Peginterferon beta-1a is an interferon therapy used for the management of relapsing forms of MS. It was originally approved by the FDA in 2014 for subcutaneous use, and was approved for intramuscular use in January 2021. Currently, it is the only approved pegylated interferon for the management of MS with an proven ability to reduce relapses and delay the progression of disability resulting from MS.
Sulindac {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Tizanidine
Tizanidine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Peginterferon beta-1a
Sulindac {u} (Compound) binds {v} (Gene) PTGS2
PTGS2 {u} (Gene) is upregulated by {v} (Compound) Fluvastatin
Fluvastatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Peginterferon beta-1a
Sulindac {u} (Compound) palliates {v} (Disease) osteoarthritis
osteoarthritis {u} (Disease) is palliated by {v} (Compound) Ketoprofen
Ketoprofen {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Peginterferon beta-1a
Sulindac {u} (Compound) is included by {v} (Pharmacologic Class) Nonsteroidal Anti-inflammatory Compounds
Nonsteroidal Anti-inflammatory Compounds {u} (Pharmacologic Class) includes {v} (Compound) Oxaprozin
Oxaprozin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Peginterferon beta-1a
Sulindac {u} (Compound) causes {v} (Side Effect) Alopecia
Alopecia {u} (Side Effect) is caused by {v} (Compound) Terbinafine
Terbinafine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Peginterferon beta-1a
Sulindac {u} (Compound) causes {v} (Side Effect) Gynaecomastia
Gynaecomastia {u} (Side Effect) is caused by {v} (Compound) Tramadol
Tramadol {u} may lead to a major life threatening interaction when taken with {v} Peginterferon beta-1a
Sulindac {u} (Compound) binds {v} (Gene) PTGS2
PTGS2 {u} (Gene) is bound by {v} (Compound) and {u} (Gene) is upregulated by {v} (Compound) Sulfasalazine
Sulfasalazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Peginterferon beta-1a
Sulindac {u} (Compound) binds {v} (Gene) SLC22A6
SLC22A6 {u} (Gene) is bound by {v} (Compound) Zidovudine
Zidovudine {u} may lead to a major life threatening interaction when taken with {v} Peginterferon beta-1a
Sulindac (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Tizanidine (Compound) and Tizanidine may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Sulindac (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is upregulated by Fluvastatin (Compound) and Fluvastatin may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Sulindac (Compound) palliates osteoarthritis (Disease) and osteoarthritis (Disease) is palliated by Ketoprofen (Compound) and Ketoprofen may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Sulindac (Compound) is included by Nonsteroidal Anti-inflammatory Compounds (Pharmacologic Class) and Nonsteroidal Anti-inflammatory Compounds (Pharmacologic Class) includes Oxaprozin (Compound) and Oxaprozin may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Sulindac (Compound) causes Alopecia (Side Effect) and Alopecia (Side Effect) is caused by Terbinafine (Compound) and Terbinafine may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Sulindac (Compound) causes Gynaecomastia (Side Effect) and Gynaecomastia (Side Effect) is caused by Tramadol (Compound) and Tramadol may lead to a major life threatening interaction when taken with Peginterferon beta-1a
Sulindac (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is bound by Sulfasalazine (Compound) and PTGS2 (Gene) is upregulated by Sulfasalazine (Compound) and Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Sulindac (Compound) binds SLC22A6 (Gene) and SLC22A6 (Gene) is bound by Zidovudine (Compound) and Zidovudine may lead to a major life threatening interaction when taken with Peginterferon beta-1a